DENVER–(BUSINESS WIRE)–WCLC — Biodesix, Inc. today announced new data regarding VeriStrat®,
a serum proteomic test, and epidermal growth factor receptor mutation
status in a Phase 1B/2 study of cabozantinib +/- erlotinib in advanced
non-small cell lung cancer is being presented at the World Conference on
Details of the presentation are as follows:
MINI 08 – Prognostic/Predictive Biomarkers (ID106)
Moderators: Thomas E. Stinchcombe, Nick Pavlakis
WCLC 2015, 09/07/2015, 04:45 PM – 06:15 PM, Mile High Ballroom 4a-4f
MINI08.04 – VeriStrat® and Epidermal Growth Factor Receptor
Mutation Status in a Phase 1B/2 study of Cabozantinib +/- Erlotinib in
Non-Small Cell Lung Cancer.
Authors: Sukhmani K. Padda, Primo Lara Jr., Scott N. Gettinger, Jeffrey
A. Engelman, Pasi A. Jänne, Howard West, Lisa Y. Zhou, Deepa S.
Subramaniam, Joseph W. Leach, Michael B. Wax, Joel W. Neal, Douglas O.
Clary, Laurie J. Goodman. Heather A. Wakelee
VeriStrat and Biodesix are registered trademarks of Biodesix, Inc.
All other trademarks referenced herein are the property of their
Biodesix’ diagnostic tests are used for earlier disease detection, more
accurate diagnosis, disease monitoring and better therapeutic guidance,
leading to improved outcomes for cancer patients. The company currently
has two tests available to clinicians, GeneStrat™ and VeriStrat®.
Used for tumor profiling, GeneStrat is an a la carte gene panel of
clinically actionable mutations. VeriStrat, a serum proteomic test,
provides physicians with prognostic and predictive information to
improve treatment decisions. In addition to developing novel diagnostics
independently, the company partners with biotechnology and
pharmaceutical companies to develop companion diagnostics to improve the
utility of therapeutic agents.
For more information about Biodesix, please visit www.Biodesix.com.
for Biodesix, Inc.
Andrea Vuturo, 1-312-997-2436